Welcome, visitor! [ Login

60% Increase in EPO Sales for First Quarter


The Company is pleased to announce revenues of US$817,500 from the sale of Erythropoietin in China for the first quarter of 2000. During the first quarter the Company recorded sales of 58,870 units, representing an increase of 60% over sales and revenues in the last quarter of 1999.

Dragon is currently in the late stages of negotiation with a major Middle Eastern pharmaceutical company for the licensing for sales and distribution of NingHongXin? rHu Erythropoietin. The Middle Eastern company has taken delivery of a large lot of sample Erythropoietin and will begin a small-scale phase II clinical trial for chronic renal failure patients undergoing hemodialysis.

The Company is also working to assemble a dossier of materials for an additional prospective licensee for registration in South East Asia, who is likely to opt for local elaboration of Dragon¡¦s rHu Erythropoietin. Dragon is also in the early stage of negotiations with a North African partner for the licensing for sales and distribution of rHu Erythropoietin in a number of African countries. Three Latin American pharmaceutical companies are also currently examining prospects for similar agreements.

Dragon Pharmaceuticals, the largest EPO producer in China, is currently a leading biotech company focusing on the research, development, production, and marketing of biodrugs.

Buy Dragon Pharma Steroids

Legit Dragon Pharma Steroid – pharmaceutical company that manufactures steroid gear: Cutting Steroid Mix for Sale.

No Tags

1826 total views, 1 today


  • Dragon Ships EPO Internationally

    Dragon Pharmaceuticals Inc. (NASDAQ OTC: DRUG) today announced that it has filled orders for recombinant erythropoietin (EPO) from Egypt, India and Peru where, in addition to China, the Company’s EPO is approved for use in the treatment of anemia related to chronic renal failure. All dollar amounts are stated in US dollars. “Penetrating new markets […]

  • Dragon Pharmaceutical Inc. Announces 2002 Fourth Quarter and Full Year Results

    Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced results for the three-month and twelve-month periods ending December 31, 2002. 2002 Highlights Generated revenues of $7.36 million, representing significant growth from $3.07 million in 2001. Enhancement of gross margin in 2002 to 86.7% from 81% in 2001. Reported a first ever operating profit of […]

  • Dragon Announces Participation at Biopartnering Europe 2001

    Dragon Pharmaceuticals Inc. (OTC BB – DRUG.OB) is pleased to announce that it has been invited to present at the BioPartnering Europe 2001 conference to be held at the Queen Elizabeth II Conference Centre in London, England from October 14th to 16th, 2001. BioPartnering Europe is the premier European venue for showcasing innovative biopharmaceutical and […]

  • Dragon Launches EPO Into the Brazilian Market

    Dragon Pharmaceuticals Inc. (OTC BB: DRUG; TSX: DDD) today announced that it has shipped an order of recombinant erythropoietin (“EPO? to Itaca Laboratorios Ltda., (“Itaca” of Brazil. Itaca, a distribution partner of the company, has won a 3.1 million Brazilian Real tender for Dragon’s EPO in the Brazilian state of Minas, Gerais, which converts to […]

  • Dragon Signs Licensing Agreement for Korea

    Dragon Pharmaceuticals Inc. (OTCBB – DRUG.OB) today announced that it has entered into a marketing and licensing agreement with Boryung Biopharma Company, Ltd. of Seoul, Korea for the distribution of recombinant Erythropoietin (EPO) in North and South Korea. According to the agreement, Boryung Biopharma will also be responsible for obtaining marketing for EPO from the […]

Dragon Pharma Suppliers

dragon pharma source
american steroids online
real dragon pharma supplier
dragon pharma for sale
dragon pharma legit supplier
buy dragon pharma
dragon pharma store
buy steroids
dragon pharma legit dragon pharma anabolics